JP2005511655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511655A5 JP2005511655A5 JP2003548819A JP2003548819A JP2005511655A5 JP 2005511655 A5 JP2005511655 A5 JP 2005511655A5 JP 2003548819 A JP2003548819 A JP 2003548819A JP 2003548819 A JP2003548819 A JP 2003548819A JP 2005511655 A5 JP2005511655 A5 JP 2005511655A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- acid
- erectile dysfunction
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 10
- 201000001881 impotence Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 6
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960003310 sildenafil Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- -1 mucate Substances 0.000 claims 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 229960000711 alprostadil Drugs 0.000 claims 2
- 229960004046 apomorphine Drugs 0.000 claims 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 229960001789 papaverine Drugs 0.000 claims 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001999 phentolamine Drugs 0.000 claims 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940066528 trichloroacetate Drugs 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000708A ITRM20010708A1 (it) | 2001-12-04 | 2001-12-04 | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
| PCT/IT2002/000758 WO2003047563A1 (en) | 2001-12-04 | 2002-12-04 | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511655A JP2005511655A (ja) | 2005-04-28 |
| JP2005511655A5 true JP2005511655A5 (enExample) | 2006-01-26 |
| JP4370169B2 JP4370169B2 (ja) | 2009-11-25 |
Family
ID=11455907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548819A Expired - Fee Related JP4370169B2 (ja) | 2001-12-04 | 2002-12-04 | 勃起障害の治療のためのアルカノイルｌ−カルニチンの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20050080018A1 (enExample) |
| EP (1) | EP1450782B9 (enExample) |
| JP (1) | JP4370169B2 (enExample) |
| KR (1) | KR100907938B1 (enExample) |
| AT (1) | ATE309800T1 (enExample) |
| AU (1) | AU2002365847A1 (enExample) |
| CA (1) | CA2465471C (enExample) |
| DE (1) | DE60207442T2 (enExample) |
| DK (1) | DK1450782T3 (enExample) |
| ES (1) | ES2250749T3 (enExample) |
| HU (1) | HU229214B1 (enExample) |
| IT (1) | ITRM20010708A1 (enExample) |
| MX (1) | MXPA04005269A (enExample) |
| PL (1) | PL211211B1 (enExample) |
| SI (1) | SI1450782T1 (enExample) |
| WO (1) | WO2003047563A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040561A1 (it) * | 2004-11-11 | 2005-02-11 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile. |
| IT1397867B1 (it) * | 2010-02-03 | 2013-02-04 | Brotzu | Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
| JP2016520564A (ja) | 2013-04-18 | 2016-07-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物、治療方法及びその使用 |
| WO2016174155A1 (en) * | 2015-04-30 | 2016-11-03 | Boehringer Ingelheim International Gmbh | Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction |
| MX2019005435A (es) | 2016-11-10 | 2019-07-10 | Boehringer Ingelheim Int | Composicion farmaceutica, metodos para tratamiento y sus usos. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
| DK0793962T3 (da) * | 1996-03-04 | 2000-05-22 | Sigma Tau Ind Farmaceuti | Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| US6133281A (en) * | 1996-10-24 | 2000-10-17 | Harbor-Ucla Research And Education Institute | NMDA receptor blockers in the therapy of urogenital disease |
| IT1293539B1 (it) * | 1997-07-16 | 1999-03-01 | Sigma Tau Ind Farmaceuti | Composizione nutritiva per soggetti in stato di debilitazione causato da stress |
| US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
| US6241471B1 (en) * | 1999-08-26 | 2001-06-05 | General Electric Co. | Turbine bucket tip shroud reinforcement |
| IT1306722B1 (it) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
-
2001
- 2001-12-04 IT IT2001RM000708A patent/ITRM20010708A1/it unknown
-
2002
- 2002-12-04 HU HU0402062A patent/HU229214B1/hu not_active IP Right Cessation
- 2002-12-04 DK DK02804338T patent/DK1450782T3/da active
- 2002-12-04 SI SI200230234T patent/SI1450782T1/sl unknown
- 2002-12-04 DE DE60207442T patent/DE60207442T2/de not_active Expired - Lifetime
- 2002-12-04 EP EP02804338A patent/EP1450782B9/en not_active Expired - Lifetime
- 2002-12-04 US US10/497,498 patent/US20050080018A1/en not_active Abandoned
- 2002-12-04 JP JP2003548819A patent/JP4370169B2/ja not_active Expired - Fee Related
- 2002-12-04 KR KR1020047007882A patent/KR100907938B1/ko not_active Expired - Fee Related
- 2002-12-04 AU AU2002365847A patent/AU2002365847A1/en not_active Abandoned
- 2002-12-04 CA CA2465471A patent/CA2465471C/en not_active Expired - Fee Related
- 2002-12-04 AT AT02804338T patent/ATE309800T1/de active
- 2002-12-04 MX MXPA04005269A patent/MXPA04005269A/es active IP Right Grant
- 2002-12-04 PL PL371131A patent/PL211211B1/pl unknown
- 2002-12-04 ES ES02804338T patent/ES2250749T3/es not_active Expired - Lifetime
- 2002-12-04 WO PCT/IT2002/000758 patent/WO2003047563A1/en not_active Ceased
-
2007
- 2007-01-05 US US11/649,796 patent/US20070117762A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,749 patent/US8343979B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2736103B2 (ja) | パーキンソン症候群の治療用医薬、およびその製造方法 | |
| JP2002521428A5 (enExample) | ||
| JP2005511655A5 (enExample) | ||
| CA2248879A1 (en) | Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases | |
| CA2465471A1 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| US8053472B2 (en) | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
| CA2505937A1 (en) | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents | |
| CN1299283A (zh) | 包含l－肉毒碱或烷酰基l－肉毒碱和nadh和/或nadph的组合物 | |
| AU780328B2 (en) | Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
| JP4706950B2 (ja) | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 | |
| EP0448523B1 (en) | Pharmaceutical compositions active on the cardiovascular system, containing 3-methylthiopropionyl L-carnitine | |
| JP2004532866A5 (enExample) | ||
| JP2008505134A5 (enExample) | ||
| JP2004532865A5 (enExample) | ||
| KR101086895B1 (ko) | 시부트라민 및 티옥트산을 포함하는 약제학적 조성물 | |
| CA2448242A1 (en) | Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain | |
| JP2004532867A5 (enExample) | ||
| JPH05194207A (ja) | 特発性精子過少症の処置のためのｌ−カルニチンおよびアシル−ｌ−カルニチンの使用 | |
| CN101087602B (zh) | L-肉碱和葡萄糖治疗心血管疾病的应用 | |
| JP2008539191A5 (enExample) | ||
| RU2000129144A (ru) | Композиция, включающая l-карнитин или алканоил l-карнитин и nadh и/или nadph | |
| HK1036589A (en) | Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |